Skip to content

Clinical observation on the application of remazolam toluenesulfonate and midazolam in critically ill patients with mechanical ventilation

Clinical observation on the application of remazolam toluenesulfonate and midazolam in critically ill patients with mechanical ventilation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046319
Enrollment
Unknown
Registered
2021-05-13
Start date
2021-05-10
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedative treatment of patients with mechanical ventilation

Interventions

remazolam toluenesulfonate group:remazolam toluenesulfonate is sedated in severe patients
midazolam group:midazolam is sedated in severe patients

Sponsors

Liaoning Health Industry Group Fukuang General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Aged from 30 to 60 years, BMI 18-28kg/m2, regardless of gender; 2.Initial RASS score >= 3, patients with mechanical ventilation by inserting respiratory tube; 3.Sign the informed consent before the activitis related to this study, understand the procedures and methods of this study, and be willing to complete this study.

Exclusion criteria

Exclusion criteria: 1.Allergy to study drugs; 2.Patients who suffer from serious diseases of central nervous system, such as coma; 3.Patients who suffer from dysfunction of important organs, such as heart, liver and kidney.

Design outcomes

Primary

MeasureTime frame
The patient achieved the dose of the target RASS score;The onset time of the drug;the changes of liver and kidney functions (serum bilirubin and serum creatinine values);the recovery time of the patients after drug withdrawal;

Secondary

MeasureTime frame
Vital signs (such as BP /HR/RR/SpO2%, etc.) and adverse reactions were recorded;

Countries

China

Contacts

Public ContactZhang Yan

Liaoning Health Industry Group Fukuang General Hospital

joida@163.com+86 15694239039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026